GlassScriptPhysician profile
Brooke A Cool
NPI 1952756538
$415.28
in general payments reported to CMS, 2019-2025
12 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $241 · 2024: $69.76 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $415.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $69.93 | 2023-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $67.55 | 2023-2025 | |
| Exact Sciences Corporation | $59.46 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $46.98 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.09 | 2023 | Spiriva Respimat, Synjardy, Jardiance |
| Amgen INC. | $27.41 | 2023 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $22.30 | 2023 | Breztri |
| Astellas Pharma US INC | $22.30 | 2023 | Veozah |
| Phathom Pharmaceuticals, INC. | $17.70 | 2025 | Voquezna |
| Alk-Abello, INC | $17.01 | 2025 | Neffy, Grastek, Odactra |
| Janssen Pharmaceuticals, INC | $14.38 | 2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $13.17 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Cool listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.